Full-Time

Director – CMC Quality Assurance

Confirmed live in the last 24 hours

Korro Bio

Korro Bio

51-200 employees

Develops RNA-based therapies for diseases

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Hybrid position at 60 first st, Cambridge, MA 02141.

Category
QA & Testing
Quality Assurance
Requirements
  • Bachelor’s or Master’s degree in a related scientific field with minimum of 8-10 years of relevant experience in the biopharmaceutical/pharmaceutical industry.
  • At least 5 years of progressively responsible experience in Quality Assurance within the pharmaceutical industry; prior management or leadership role preferred.
  • Previous experience with FDA inspections and interaction with FDA.
  • Expert knowledge of GMP regulations; strong knowledge of FDA, and CHMP/EU regulations.
  • Demonstrated record in effectively managing and implementing GMP-compliant quality systems.
  • Experience supporting early phase clinical through commercial manufacturing, including the use of contract manufacturers.
  • Experience in RNA therapeutics and LNP-formulated drugs is highly desirable.
  • Builds effective interactions with a broad range of internal and external organizations, teams, and individuals.
  • Ability to think critically and take a collaborative approach to problem-solving.
  • Excellent verbal and written communication skills.
  • Ability to work effectively in a regulated and fast-paced environment.
  • Demonstrates an elevated level of professional integrity and trustworthiness with strong work ethics.
  • Able to travel domestically and internationally.
Responsibilities
  • Acts as the key Quality Assurance CMC lead on program teams.
  • Participates in the evaluation and selection of contract manufacturing sites, analytical testing sites, clinical storage, and distribution depots, and other service providers used to support the clinical development programs.
  • Monitors third-party vendor performance, and oversees logistics of vendors for compliance including FIH and late phase activities.
  • Oversees GMP and GLP compliance audits (US and international), including contract manufacturing sites, analytical testing sites, contract test laboratories, and CROs to determine compliance status and to identify compliance risks.
  • Review process and method validation protocols and reports.
  • Oversees the QA reviews of GMP manufacturing batch records, product release and stability testing, validation reports, pharmacology and toxicology study reports.
  • Review and approve specifications affecting product quality.
  • Disposition of clinical and commercial batches.
  • Provide key input towards development of corporate quality policies, systems and procedures.
  • Review and approve change controls, deviations, investigations, CAPA, and Product Quality Complaints.
  • Interacts with manufacturing, clinical, operations, or other functional areas as they impact quality operations and ensures cross-functional completion of issues or identified actions.
  • Assist in updating CMC sections of regulatory and quality documents.
  • Organize and manage QA CMC employee training programs, initiate training sessions including specific GxP training, and maintain training records.
  • Participate in risk assessment, review and approve reports.
  • Participate in hosting regulatory inspections.
  • Prompt communication to management of critical and/or compliance issues.

Korro Bio develops RNA-based therapies aimed at treating serious diseases that currently lack effective treatments. The company uses RNA editing to make precise modifications at the RNA level, which allows for accurate changes to protein function. This method is seen as more precise and potentially safer than traditional gene editing techniques. Korro Bio focuses on research and development to create new therapies, which it can market independently or through partnerships with larger pharmaceutical companies. The company serves healthcare providers, hospitals, and patients, and collaborates with academic institutions to enhance its research. Korro Bio's goal is to make significant scientific advancements in medicine accessible to patients in need.

Company Stage

N/A

Total Funding

$383.7M

Headquarters

Cambridge, Massachusetts

Founded

2019

Growth & Insights
Headcount

6 month growth

4%

1 year growth

0%

2 year growth

17%
Simplify Jobs

Simplify's Take

What believers are saying

  • The $70 million raised for clinical trials and growth positions Korro Bio to advance its pipeline and achieve significant milestones.
  • The appointment of industry veterans like Dr. Rachel Meyers and Tim Pearson to the board strengthens the company's leadership and strategic direction.
  • Korro Bio's stock price surge of 171% in November indicates strong market confidence and potential for high returns.

What critics are saying

  • The biopharmaceutical market is highly competitive, and Korro Bio must continuously innovate to maintain its edge.
  • The success of RNA editing therapies is still uncertain and hinges on successful clinical trials and regulatory approvals.

What makes Korro Bio unique

  • Korro Bio's focus on RNA editing allows for precise single base modifications, offering a potentially safer and more accurate alternative to traditional gene editing and gene therapy.
  • The company's strategy of leveraging machine learning to enhance RNA delivery and platform development sets it apart from competitors.
  • Korro Bio's recent $70 million private placement and merger with Frequency Therapeutics provide substantial financial backing and expanded capabilities.

Help us improve and share your feedback! Did you find this helpful?